Evidence-based therapies are available for the acute symptomatic treatment of migraine in children and adolescents, but evidence is lacking for the impact of many treatments for migraine prevention.
The injection of onabotulinumtoxinA toward the sphenopalatine ganglion in patients with trigeminal neuralgia may not reduce the number of attacks.
Remote electrical neuromodulation may represent a safe and effective option for the acute treatment of migraine.
The brief, parent-report Psychosocial Assessment Tool 2.0_General questionnaire may be effective for screening psychosocial risks in children and adolescents with recurrent headache.
Higher levels of caffeinated beverage intake may be a trigger for migraine headache on that day among adults with episodic migraines.
Galcanezumab, a monoclonal antibody against calcitonin gene-related peptide, may significantly improve daily functioning, disability, and health-related quality of life in a rapid and sustained fashion in patients with migraine.
Botulinum toxin was found to reduce migraine frequency in adults with chronic migraine by two days per month without significant adverse events.
The use of a smartphone-based progressive muscle relaxation was found to be associated with a reduction in monthly headache days and depression scores in patients with migraine.
Galcanezumab was found to be beneficial in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.
Lasmiditan may provide effective acute relief from migraine, with sustained improvements in freedom from pain, most bothersome symptoms, total migraine, and disability.
